LRRC42: A Potential Drug Target and Biomarker for Diseases (G115353)

Target Name: LRRC42

NCBI ID: G115353

LRRC42

LRRC42: A Potential Drug Target and Biomarker for Diseases

LRRC42 (Long non-coding RNA gene LRRC42) is a protein that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. LRRC42 is a long non-coding RNA gene that is expressed in various tissues and cells throughout the body. It is characterized by a unique structure that consists of a long intergenic non-coding RNA molecule (lncRNA) that is surrounded by a protein-coding gene.

The LRRC42 gene was first identified in the human genome in 2008 using transcriptome sequencing techniques. Since then, research has identified LRRC42 as being involved in various cellular processes, including cell adhesion, migration, and invasion. LRRC42 has also been shown to play a role in regulating gene expression and has been linked to various diseases, including cancer.

One of the key features of LRRC42 is its ability to interact with other proteins, including the protein tyrosine kinase (PTK) signaling pathway. This interaction between LRRC42 and PTK has led to the identification of LRRC42 as a potential drug target for various diseases.

LRRC42 has been shown to play a role in the regulation of cell proliferation and has been linked to the development of various types of cancer. For example, studies have shown that LRRC42 is highly expressed in various cancer tissues and that it is associated with poor prognosis in cancer patients. Additionally, LRRC42 has been shown to promote the growth and survival of cancer cells, making it a potential therapeutic target.

LRRC42 has also been shown to be involved in the regulation of cell migration and invasion. This has led to the hypothesis that LRRC42 may play a role in the development of invasive and metastatic diseases. For example, studies have shown that LRRC42 is highly expressed in various invasive and metastatic tissues and that it is associated with the development of cancer.

In addition to its role in cell biology, LRRC42 has also been shown to be involved in the regulation of gene expression and has been linked to the development of various diseases. For example, studies have shown that LRRC42 is involved in the regulation of microRNA (miRNA) expression and that this regulation is associated with the development of neurodegenerative diseases.

LRRC42 has also been shown to play a role in the regulation of inflammation and has been linked to the development of autoimmune disorders. This has led to the hypothesis that LRRC42 may play a role in the development of autoimmune diseases. For example, studies have shown that LRRC42 is highly expressed in various autoimmune tissues and that it is associated with the development of rheumatoid arthritis.

In conclusion, LRRC42 is a protein that has been identified as a potential drug target and biomarker for various diseases. Its unique structure and various functions, including its ability to interact with other proteins and its role in cell biology, cell migration, and invasion, make it an attractive target for drug development. Further research is needed to fully understand the role of LRRC42 in diseases and to develop safe and effective therapies based on it.

Protein Name: Leucine Rich Repeat Containing 42

The "LRRC42 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LRRC42 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets